Skip to content

Circles

R

Revium Rx.

RVRC· OTC

R

RVRCRevium Rx.

RVRCRevium Rx.·Earnings record

Q1 2025

Source filing unavailable

Next · Q2 2025

Q1 2025 · —

Revenue—

Net Income

-$634.00K

no prior Q1 2024 on file

EPS Diluted

$0.01

no prior Q1 2024 on file

Operating Income-$737,000—

Operating Cash Flow-$357,000—

Same quarter

no prior Q1 2024 on file

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Filing lag

Quarterly history

Q1 ’25Q2 ’25 Q1 ’26 Q2 ’26

Revium Rx. · CIK 1839140 · Engraved from SEC EDGAR

Thaler ResearchEngraved from SEC EDGAR© 2026 Thaler. All rights reserved.Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Platform

Using AI API SDKs CLI

Research

News Listen Earnings Insiders Holders Compare Metrics

Screener Watchlists Pies Notes Your companies

Learn

Thaler

Thaler Agent Promise Provenance Circles Account Terms Privacy